SCHEMBL6326434

SCHEMBL6326434

COc1ccc(-c2ccc(S(=O)O)cc2)cc1.[LiH]

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR2 Q92731 1/20 0.52
NPC1 O15118 2/20 0.47
RAB9A P51151 2/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
TP53 P04637 1/20 0.47
MAPK1 P28482 1/20 0.47
CASP3 P42574 1/20 0.47
SENP8 Q96LD8 1/20 0.47
SENP7 Q9BQF6 1/20 0.47
SENP6 Q9GZR1 1/20 0.47
ME2 P23368 1/20 0.44
ME1 P48163 1/20 0.44
ME3 Q16798 1/20 0.44
CA1 P00915 2/20 0.44
CA2 P00918 2/20 0.44
CA12 O43570 1/20 0.44
CA7 P43166 1/20 0.44
CA9 Q16790 1/20 0.44
CA14 Q9ULX7 1/20 0.44
BACE1 P56817 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14124827 0.98 ESR2 (0.54) ESR2NPC1RAB9ASMN1; SMN2TP53
SCHEMBL7513563 0.94 CA1 (0.50) ESR2NPC1RAB9ASMN1; SMN2MAPK1
SCHEMBL6368286 0.92 CA1 (0.52) ESR2NPC1RAB9ASMN1; SMN2MAPK1
SCHEMBL7514704 0.90 CA1 (0.50) ESR2NPC1RAB9ASMN1; SMN2MAPK1
SCHEMBL11297957 0.90 CA1 (0.50) ESR2NPC1RAB9ASMN1; SMN2MAPK1
SCHEMBL357933 0.90 CA1 (0.50) ESR2NPC1RAB9ASMN1; SMN2MAPK1
SCHEMBL14124758 0.86 LTA4H (0.54) NPC1RAB9ASMN1; SMN2CA1CA2
SCHEMBL10606718 0.80 ESR1 (0.35) ESR2
Lithium Ion SCHEMBL6326431 0.76 ESR2 (0.47) ESR2NPC1RAB9ASMN1; SMN2TP53
Diphenylmethanol SCHEMBL10871922 0.75 ACP3 (0.49) NPC1RAB9ASMN1; SMN2TP53MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050014840-A1 Thiol sulfonamide metalloprotease inhibitors PHARMACIA CORPORATION 2005-01-20 US disclosed
US-6747027-B1 SELECTIVELY INHIBITS IN VITRO ACTIVITY OF HUMAN MATRIX METALLOPROTEASE-13 OVER IN VITRO ACTIVITY OF HUMAN MATRIX METALLOPROTEASE-1 PHARMACIA CORPORATION 2004-06-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050014840-A1 Thiol sulfonamide metalloprotease inhibitors MMP12, MMP13, MMP3 ESR2 3669/4885NPC1 3786/4885RAB9A 3653/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.